April 2026 FDA Recall Liraglutide by Lupin Pharmaceuticals Inc.
D-0541-2026 - Presence of particulate matter

This Class II drug recall was voluntarily initiated by Lupin Pharmaceuticals Inc. on April 24, 2026 for the product Liraglutide. The FDA reported the reason for recall as presence of particulate matter. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0541-2026

Reason for Recall
Presence of particulate matter: a white thread-like structure in the cartridge
Initiated
04-24-2026
Reported
05-27-2026
Quantity
217,621 pen injectors

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Lupin Pharmaceuticals Inc.
Nationwide within U.S
Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, Manufactured by: Lupin Limited, Nagpur 441108, INDIA, a) 2 Pens- NDC 70748-346-02; b) 3 Pens - NDC 70748-346-03.

Batch or Lot Expiration Information

Lot# Lots: a) WB00097, WB00094, WB00088, Expires: Jul. 2027; WB00103, Expires: Oct. 2027; WC00016, Expires: Dec. 2027; b) WB00098, WB00092, WB00093, Expires: Jul. 2027; WB00104, WB00106, WB00105, Expires: Oct. 2027.

Affected Packages Involved in this Recall